1 – 50 of 91
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
(
- Contribution to journal › Article
- 2022
-
Mark
Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
(
- Contribution to journal › Article
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
-
Mark
Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres
(
- Contribution to journal › Article
-
Mark
Selumetinib Plus Adjuvant Radioactive Iodine in Patients with High-Risk Differentiated Thyroid Cancer : A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
(
- Contribution to journal › Article
- 2021
-
Mark
Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
(
- Contribution to journal › Article
- 2020
-
Mark
Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines
(
- Contribution to journal › Article
- 2019
-
Mark
The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease
(
- Contribution to journal › Article
- 2018
-
Mark
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
(
- Contribution to journal › Article
- 2017
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article
- 2015
-
Mark
Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
-
Mark
Long-term retention of 177Lu/177mLu-Dotatate in patients investigated by gamma spectrometry and gamma camera imaging.
(
- Contribution to journal › Article
-
Mark
Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
- 2014
-
Mark
Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Change in Cell Death Markers During (177)Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma.
(
- Contribution to journal › Article
-
Mark
Fellowship framgångssaga i Lund
(
- Contribution to journal › Debate/Note/Editorial
- 2013
-
Mark
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.
(
- Contribution to journal › Article
-
Mark
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
(
- Contribution to journal › Article
- 2012
-
Mark
Repeated Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody.
(
- Contribution to journal › Article
-
Mark
Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
(
- Contribution to journal › Article
-
Mark
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
(
- Contribution to journal › Article
- 2011
-
Mark
Different toxicity profiles for drug-versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model
(
- Contribution to journal › Article
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
-
Mark
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds
(
- Contribution to journal › Article
- 2010
-
Mark
Toxicity-Reducing Potential of Extracorporeal Affinity Adsorption Treatment in Combination With the Auristatin-Conjugated Monoclonal Antibody BR96 in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
-
Mark
High-Dose Radioimmunotherapy Combined With Extracorporeal Depletion in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
-
Mark
90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
-
Mark
Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial
2010) 35th European-Society-for-Medical-Oncology (ESMO) Congress In Annals of Oncology 21. p.315-315(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.
(
- Contribution to journal › Article
-
Mark
Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
2009) 6th Annual Conference of the European-Neuroendocrine-Tumor-Society In Neuroendocrinology 90(1). p.44-44(
- Contribution to journal › Published meeting abstract
-
Mark
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
(
- Contribution to journal › Article
- 2008
-
Mark
Evaluation of toxicity-reducing potential of ECAT in combination with drug-conjugated mAb BR96
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.520-520(
- Contribution to journal › Published meeting abstract
-
Mark
Consequences of Inadvertent Radioiodine Treatment of Graves' Disease and Thyroid Cancer in Undiagnosed Pregnancy. Can We Rely on Routine Pregnancy Testing?
(
- Contribution to journal › Article
-
Mark
Peptide receptor radionuclide therapy (PRRT) using Lu-177-Dotatate: Early clinical and dosimetric results
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.524-525(
- Contribution to journal › Published meeting abstract
-
Mark
High dose radioimmunotherapy combined with extracorporeal depletion in syngeneic rat tumor model. Evaluation of toxicity, therapeutic effect, and tumor model
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.517-517(
- Contribution to journal › Published meeting abstract
-
Mark
Guidelines for radioiodine therapy of differentiated thyroid cancer
(
- Contribution to journal › Scientific review
- 2007
-
Mark
EANM procedure guideline for (32)P phosphate treatment of myeloproliferative diseases.
(
- Contribution to journal › Article
-
Mark
A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats.
(
- Contribution to journal › Article
-
Mark
Combined flow cytometry and confocal laser scanning microscopy for evaluation of BR96 antibody cancer cell targeting and internalization.
(
- Contribution to journal › Article
-
Mark
Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood.
(
- Contribution to journal › Article
-
Mark
Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy
(
- Contribution to journal › Article
-
Mark
Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
(
- Contribution to journal › Article
-
Mark
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray"
(
- Contribution to journal › Scientific review
-
Mark
Targeted therapy in nuclear medicine current status and future prospects
(
- Contribution to journal › Article
-
Mark
EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with (90)Y-radiolabelled ibritumomab tiuxetan (Zevalin).
(
- Contribution to journal › Article
-
Mark
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
(
- Contribution to journal › Article